Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

Inclusion Criteria: * Patient must be at least 18 years of age. * Primary diagnosis of uveal melanoma as clinically determined by the treating investigator planned for enucleation (prior plaque brachytherapy is permitted) * Patient is able to provide written, informed consent before initiation of any study related-procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study. * Life expectancy \> 3 months. * Able to safely swallow orally administered medication. * Patients with a prior history of or clinically stable concurrent malignancy are eligible for enrolment provided the malignancy is clinically insignificant, no treatment is required, and the patient is clinically stable * Patients with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled. * Patients with prostate cancer with an elevated PSA not requiring treatment may be enrolled * Patient has Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 (Karnofsky = 70%). * Patient has adequate organ function at screening: * Absolute neutrophil count = 1500/mm3 without the use of hematopoietic growth factors * Platelet count = 75,000/mm3 (must be at least 2 weeks post-platelet transfusion and not receiving platelet-stimulating agents) * Haemoglobin = 8.0 g/dL (must be at least 2 weeks post-red blood cell transfusion and not receiving erythropoietic-stimulating agents) * Total bilirubin = 1.…